The biomarker validation strengthens evorpacept's clinical rationale, potentially increasing partnership or acquisition interest. The extended cash runway reduces immediate dilution risk, but the large share issuance (over 95M shares/warrants) implies significant dilution for existing shareholders. Traders should monitor upcoming data readouts at ESMO 2026 and mid-2027 as key catalysts.
Price Chart
Executive Summary
ALX Oncology reported Q4 and full-year 2025 financial results alongside clinical updates, highlighting biomarker validation for evorpacept in HER2-positive cancers and progress on its ALX2004 program. The company completed a $150 million equity offering, extending its cash runway into 1H 2028. While R&D and net losses declined year-over-year, there were no revenue-generating products, and the company remains in clinical development.
Key Financial Metrics
Key Facts
- Evorpacept demonstrated strong biomarker-driven efficacy: 65% ORR and 25.5-month mDOR in CD47-high/HER2-positive gastric cancer patients.
- Company completed $150M registered offering, raising $140.4M in net proceeds, extending cash runway to 1H 2028.
- R&D expenses decreased to $77.0M in 2025 from $116.4M in 2024; net loss improved to $101.7M from $134.9M.
- Phase 2 ASPEN-09-Breast trial enrollment expanded to up to 120 patients, with topline data expected mid-2027.
- Safety data from ALX2004 Phase 1 dose-escalation trial expected in 2H 2026.
Financial Impact
Cash increased from $48.3M to ~$188.7M post-offering, reducing near-term funding risk. R&D spending down 33.8% YoY, improving efficiency.
Risk Factors
- High dilution from equity offering: over 95M new shares and warrants issued, increasing share count by ~177% based on current ~54M shares.
- No near-term revenue: ALXO remains a pre-revenue biotech with clinical-stage assets, dependent on trial outcomes and future financing.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3246481 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 16, 2026 9d ago | SC 13D/A | $1.14 $1.13 | ▼ −0.88% | ▼ −0.73% | $1.13 (−0.88%) |
Oct 15, 2026 11d ago | 8-K | $1.06 $1.17 | ▲ +10.38% | ▲ +10.81% | $1.13 (+6.60%) |
Sep 28, 2026 28d ago | Press Release | $1.39 $1.21 | ▼ −12.95% | ▼ −14.15% | $1.13 (−18.71%) |
Aug 15, 2026 10w ago | Institutional Cluster | $1.97 $1.99 | ▲ +1.02% | ▲ +2.21% | $1.13 (−42.64%) |
Aug 6, 2026 11w ago | 8-K | $2.11 $1.94 | ▼ −8.06% | ▼ −9.27% | $1.13 (−46.45%) |
Jun 30, 2026 16w ago | 8-K | $2.06 $2.36 | ▲ +14.56% | ▲ +14.30% | $1.13 (−45.15%) |
Jun 26, 2026 17w ago | 8-K | $2.20 $2.19 | ▼ −0.45% | ▼ −1.84% | $1.13 (−48.64%) |
Jun 12, 2026 19w ago | Institutional Cluster | $1.58 $1.53 | ▲ +3.16% | ▲ +3.84% | $1.13 (+28.48%) |
May 8, 2026 24w ago | 8-K | $2.08 $2.04 | ▼ −1.92% | ▼ −3.39% | $1.13 (−45.67%) |
May 8, 2026 24w ago | Press Release | $2.08 $2.04 | ▲ +1.92% | ▲ +3.39% | $1.13 (+45.67%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers